Esomeprazole
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Esomeprazole: Predicted New Indication of Duodenogastric Reflux
One-Sentence Summary
Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid, and it is registered in South Africa in three products. The TxGNN model predicts it may be useful for duodenogastric reflux, but only 1 general review article and no clinical trials currently support this direction.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Duodenogastric reflux |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the input. From general PPI pharmacology, esomeprazole irreversibly inhibits the gastric H+/K+ ATPase (the proton pump), which reduces acid injury to the stomach lining.
Duodenogastric (bile) reflux is mainly a non-acid process, so the mechanistic fit is weak. A PPI could at most relieve symptoms by lowering the acid component of the refluxate. It would not stop the reflux itself. The high model score (99.53%) is therefore better read as a knowledge-graph association than as evidence of a true therapeutic effect.
Other predicted indications for this drug have much stronger support, notably duodenal ulcer (rank 3, Phase 3 evidence) and active peptic ulcer disease (rank 4, Phase 4 and Phase 2 evidence). These are acid-related conditions and probably reflect existing PPI use rather than true repurposing.
Clinical Trial Evidence
Currently no related clinical trials registered for duodenogastric reflux.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18679668 | 2008 | Review | European Journal of Clinical Pharmacology | General update on PPI clinical use and pharmacokinetics. It covers peptic ulcer, H. pylori infection, gastro-oesophageal reflux disease, NSAID-induced lesions and Zollinger-Ellison syndrome. It does not address duodenogastric reflux directly. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 51/11.4.3/0932 | Nectizole Iv | Infusion |
| Reg. No. 45/11.4.3/0121 | Nexipraz Otc | Tablet |
| Reg. No. 45/3.1/0179 | Vimovo 500/20mg | Tablet |
Available routes are injectable (infusion) and oral (tablet).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials and only one general review. Bile reflux is largely non-acid, so the mechanistic link is weak. Esomeprazole is already marketed in South Africa, but nothing in the input supports using it for this specific condition.
To proceed, the following is needed:
- SAHPRA package insert data (approved indications, warnings, contraindications), which is currently missing and blocks safety screening
- Mechanism of action data from DrugBank
- Clinical or observational studies of PPIs in duodenogastric (bile) reflux, to show whether symptom relief occurs
- A separate review of duodenal ulcer and active peptic ulcer disease, which have the strongest evidence in this pack, to confirm whether they are already covered by the registered indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.